Organ Preservation After iTNT Tracks With Better Daily Function in Rectal Cancer
Immunotherapy-based total neoadjuvant therapy is changing what rectal cancer treatment can look like after tumor response, but the long view has mattered more than the initial response rate. In this prospective longitudinal cohort, patients who achieved organ preservation after immunotherapy-based total neoadjuvant therapy experienced more favorable long-term quality of life and anorectal function than those who went on to total mesorectal excision. The difference was not abstract. It showed up in global health status, symptom burden, and bowel function scores that shape how patients actually live after treatment.
The study followed patients treated from 2021 to 2024 and used repeated patient-reported outcome instruments rather than a single post-treatment snapshot. That design matters because rectal cancer survivorship often turns on the evolution of bowel control, urgency, and social confidence, not simply disease control. The investigators tracked outcomes with the EORTC QLQ-C30 and CR29, the Low Anterior Resection Syndrome scale, the Wexner incontinence score, and the Memorial Sloan Kettering Cancer Center Bowel Function Instrument. Linear mixed-effects models were used to account for repeated measures within the same patient, a sensible approach for a cohort in which bowel function can change over time as healing, adaptation, and surgical consequences unfold.
How Surgery Choice Shaped Patient-Reported Outcomes
Of 172 patients who received iTNT, 142 were eligible for quality-of-life analysis and 137 were assessed for anorectal function after five patients with permanent stomas were excluded. The comparison between organ preservation and radical surgery was consistent across the outcome tools. Patients managed with organ preservation had better global health status, lower symptom burden, and better anorectal function than those undergoing total mesorectal excision. Their LARS and Wexner scores were lower during follow-up, indicating fewer problems with bowel clustering, urgency, leakage, and continence-related distress.
Those findings fit the biology of treatment injury. Total mesorectal excision, even when technically successful, can disrupt pelvic nerves, shorten the functional rectum, and alter reservoir capacity, leaving patients with the classic cluster of symptoms captured by LARS instruments. Organ preservation avoids much of that anatomical insult. When the tumor has responded enough to permit watchful management rather than immediate resection, the rectum remains in place and the pelvic floor is spared the mechanical consequences of surgery. In practical terms, that can translate into better toilet predictability, less fear of accidents, and more stable participation in ordinary daily routines.
The study also included a separate conventional total neoadjuvant therapy cohort for exploratory comparison. In that cross-sectional analysis, poorer quality-of-life and anorectal outcomes after iTNT were mainly seen among patients who underwent TME, while patients managed with organ preservation had outcomes that were largely comparable to those in the conventional TNT group. The pattern suggests that the functional penalty is driven less by the systemic therapy platform itself than by the local treatment that follows response assessment.
Bowel Function Divergence Was Most Visible After TME
One sentence captures the central clinical divide: radical surgery carried the heavier functional cost.
Major LARS did not fall evenly across the cohort. Multivariable analysis identified total mesorectal excision and shorter tumor distance from the anal verge as independent risk factors for major LARS. The anatomic explanation is straightforward. Tumors closer to the anal verge usually force surgery into a narrower pelvic corridor, where margins are tighter and the rectal reservoir is smaller even before treatment begins. Add resection, and the patient starts with less capacity for normal storage and evacuation. The consequence is a higher likelihood of clustering, urgency, and incomplete control, especially when the distal rectum has been affected by both tumor location and treatment-related changes.
The study’s statistical approach strengthens the inference, because the risk factor analysis used both univariable and multivariable logistic regression with multiple imputation and complete-case sensitivity analyses. In other words, the association between surgery type and major LARS did not depend on one isolated analytic choice. It persisted after accounting for missing data and after adjusting for other measured factors.
Why the Findings Matter for Rectal Cancer Decision-Making
The appeal of iTNT lies in response deep enough to open the door to organ preservation. These data show why that door matters well beyond avoiding a stoma. Quality of life in rectal cancer is tightly linked to bowel function, and bowel function is often the domain where patients feel the lasting burden of treatment. A patient who avoids radical surgery may also avoid the chronic bowel unpredictability that can dominate survivorship, especially when the tumor is distal and the anticipated functional reserve is already limited.
This is the kind of outcome that can shift discussions in clinic. For appropriately selected patients, the choice is not only between curing cancer and sparing an organ. It is also between two different long-term functional futures. One path preserves the rectum and often preserves daily autonomy. The other may provide oncologic certainty at the price of persistent bowel dysfunction, even when the surgery is technically complete.
Limits of the Cohort and the Remaining Clinical Gap
The analysis was prospective and longitudinal, but it was still observational. Patients were not randomized to organ preservation or total mesorectal excision, so treatment choice likely reflected response, anatomy, and clinical judgment. That leaves room for selection effects that can influence patient-reported outcomes. The conventional TNT comparison was exploratory and cross-sectional rather than a randomized benchmark. Five patients with permanent stomas were excluded from the functional analysis, which is reasonable for the study question but also narrows the lens on how postoperative bowel outcomes are measured.
Even with those constraints, the clinical direction is hard to ignore. Among rectal cancer patients treated with iTNT, organ preservation was linked to better long-term quality of life and anorectal function than radical surgery. The functional cost of TME, especially in tumors closer to the anal verge, remains central to treatment planning. Future studies will need to clarify how best to select patients for organ preservation and how durable these patient-reported advantages remain as follow-up extends beyond the current cohort window.